Trees Corporation (CANN) Fair Value & Analysis

Healthcare · US · Market cap $2.1M

Below-average quality, screening 17% undervalued on our models.

What matters now

• The price is below even our cautious bear case ($0.0209). The market is more pessimistic than our downside scenario.
• The models converge in a tight band ($0.0209 to $0.0234), unusually little disagreement for a valuation.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 29, 2026.

How to read this chart

60‑month range $0.0002 – $0.8650 · fair‑value band $0.0209 – $0.0234 · the $0.0179 price screens below the $0.0209 fair value. Dashed = 300-day average. As of Jul 29, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Trees Corporation (CANN) currently trades at $0.0179, while our model-based Fair Value estimate is $0.0209, implying the stock looks roughly 16.8% undervalued today. The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, Trees Corporation generated revenue of $14.5M at a net margin of -37.1%. Revenue declined 19.5% year over year. Net debt stands at $21.3M. Fundamentals as of Jul 29, 2026

Our scenario range runs from $0.0209 (bear case) to $0.0234 (bull case); at $0.0179, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 69% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 17%, CANN screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Multiples ($0.0200) versus Dividend Discount ($0.0100). Highest evidence: Gordon GGM (70).

Key figures & financial health

Quality Score breakdown

About the company

Trees Corporation operates as a cannabis retailer and cultivator in the United States. The company operates through Retail and Cultivation segments.

Full company description

Trees Corporation operates as a cannabis retailer and cultivator in the United States. The company operates through Retail and Cultivation segments. The company offers cannabis flower, shake, wax, shatter, live resin, and other products, as well as joints, and vape cartridges and batteries; and gummies, taffy, hard candies, cookies, chocolate bars, and savory snacks. It also provides smoking accessories, including glass pipes and rigs, lighters, torches, and rolling papers; soda and juice products, tinctures, and elixirs; creams and lotions, oils, salves, transdermal patches, and balms; and t-shirts, sweat shirt, hoodies, hats, and stickers under the Trees Dispensaries brand name. In addition, the company operates cannabis dispensaries and cultivation facilities. Trees Corporation was formerly known as General Cannabis Corp. and changed its name to Trees Corporation in June 2022. The company is headquartered in Lakewood, Colorado.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Trees Corporation reported revenue of $11.7M in FY2025 versus $5.9M in FY2021, a compound +18.4%/yr. Reported net income was −$843K in FY2025.

Watch CANN: get an alert when its fair value changes →

Peer Group

Drug Manufacturers - Specialty & Generic · 623 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 29, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.